Clobetasol 0.05% ointment ( DrugBank: Clobetasol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 39 | Toxic epidermal necrolysis | 1 |
39. Toxic epidermal necrolysis
Clinical trials : 13 / Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02319616 (ClinicalTrials.gov) | November 2016 | 15/12/2014 | Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis | A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) | Toxic Epidermal Necrolysis | Drug: Clobetasol 0.05% ointment;Drug: Placebo | University of California, Davis | NULL | Withdrawn | 7 Years | 85 Years | All | 0 | Phase 1/Phase 2 | United States |